Shorla Oncology has signed a licensing agreement and strategic collaboration with an undisclosed drug development and production firm in the UK for a chemotherapy drug, PIP-101. 

Shorla will obtain a licence from the UK company to register and market the drug in the US.

PIP-101 is an oral solution that reduces or hinders the growth of some types of leukaemia, including chronic myeloid leukaemia and acute lymphoblastic leukaemia.

The developer will produce PIP-101 and once Shorla receives a new drug application clearance, it will oversee the launch, marketing and sales of the drug in the US.

Shorla Oncology CEO and co-founder Sharon Cunningham stated: “We are excited to partner with and leverage the developer’s oral oncology liquid manufacturing expertise. 

“This commercial partnership is a strong endorsement of our commitment to bring to market differentiated oncology treatments to address key areas of unmet needs for patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March 2023, the company received approval from the US Food and Drug Administration for its Nelarabine injection to treat T-cell leukaemia.

The company is partnering with Eversana to launch this injection commercially.

By the end of 2024, Shorla anticipates making its three products available in the market and having at least three further products at a developmental stage.